Karyopharm Therapeutics
(NASDAQ:KPTI)
$1.09
0.02[1.87%]
At close: May 10
$1.09
0[0.00%]
After Hours: 7:11PM EDT
Q1 2024 Earnings were released on Wed May 8th, before the market open
The most recent conference call was at 8:00 AM, 3 days ago Click to view past webcast
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Karyopharm Therapeutics Stock (NASDAQ:KPTI), Quotes and News Summary

Karyopharm Therapeutics Stock (NASDAQ: KPTI) stock price, news, charts, stock research, profile.

Open$1.050
Close$1.090
Volume / Avg.1.130M / 1.376M
Day Range1.020 - 1.110
52 Wk Range0.617 - 2.790
Market Cap$126.948M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
45
Short Interest
20.66%
Days to Cover23.33

Recent News

Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation
Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced the presentation of updated exploratory subgroup analyses from the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the virtual American Society of Clinical 
Vandana Singh
Why Are Karyopharm Therapeutics Shares Gaining Today?
Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-
Vandana Singh
Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's main product.
Lisa Levin
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Mar
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
KPTI
SYRS

FAQ

Q

How do I buy Karyopharm Therapeutics (KPTI) stock?

A

You can purchase shares of Karyopharm Therapeutics (NASDAQ: KPTI) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Karyopharm Therapeutics's (KPTI) competitors?

A

Other companies in Karyopharm Therapeutics’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Molecular Partners (NASDAQ:MOLN), CytomX Therapeutics (NASDAQ:CTMX), Cellectar Biosciences (NASDAQ:CLRB) and FibroGen (NASDAQ:FGEN).

Q

What is the target price for Karyopharm Therapeutics (KPTI) stock?

A

The latest price target for Karyopharm Therapeutics (NASDAQ: KPTI) was reported by HC Wainwright & Co. on Thursday, May 9, 2024. The analyst firm set a price target for 8.00 expecting KPTI to rise to within 12 months (a possible 633.94% upside). 11 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Karyopharm Therapeutics (KPTI)?

A

The stock price for Karyopharm Therapeutics (NASDAQ: KPTI) is $1.09 last updated May 10, 2024 at 7:11 PM EDT.

Q

Does Karyopharm Therapeutics (KPTI) pay a dividend?

A

There are no upcoming dividends for Karyopharm Therapeutics.

Q

When is Karyopharm Therapeutics (NASDAQ:KPTI) reporting earnings?

A

Karyopharm Therapeutics’s Q2 earnings are confirmed for Wednesday, July 31, 2024.

Q

Is Karyopharm Therapeutics (KPTI) going to split?

A

There is no upcoming split for Karyopharm Therapeutics.

Q

What sector and industry does Karyopharm Therapeutics (KPTI) operate in?

A

Karyopharm Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch